MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Ancillary Service Utilization and Impact in Huntington’s Disease

J. Yomtoob, C. Yeh, D. Bega (Chicago, IL, USA)

Meeting: 2019 International Congress

Abstract Number: 55

Keywords: Chorea (also see specific diagnoses, Huntingtons disease, etc): Clinical features, Chorea (also see specific diagnoses, Huntingtons disease, etc): Treatment, Multidisciplinary Approach

Session Information

Date: Monday, September 23, 2019

Session Title: Huntington’s Disease

Session Time: 1:45pm-3:15pm

Location: Agora 3 West, Level 3

Objective: To determine which Huntington’s disease (HD) patient characteristics correlate with ancillary service utilization. To examine the longitudinal impact of ancillary therapies on clinical characteristics.

Background: Prior HD studies suggest that ancillary services may improve motor symptoms, cognition, mood, and quality of life. It is unclear how often they are provided. Data are needed to understand their role in treatment and which patients receive them.

Method: Retrospective cross-sectional analysis of the Enroll-HD database. Patients were grouped by therapy: physical and/or occupational (PT/OT), psychotherapy and/or counseling, speech and/or swallowing (ST). Bivariate comparisons were conducted for demographic and disease characteristics between those with/without each therapy and to analyze one-year mean change in assessment scores.

Results: 4751 patients were included. 1537 (32.35%) utilized therapies (11.82% PT/OT, 5.33% psychotherapy/counseling, 3.01% ST, 1.98% all three, 10.21% two therapies).The PT/OT group had worse motor and functional scores compared to the “no PT/OT” group: mean UHDRS motor score (41.17 vs. 38.05, OR= 1.006, p=0.002), median total functional capacity score (TFC) (8.00 vs. 9.00, OR= 0.958, p<0.001). The psychotherapy/counseling group had worse mood but better cognitive and functional scores compared to the “no psychotherapy” group: median depression score (7.00 vs. 2.00, OR= 1.069, p<0.001), median MMSE (28.00 vs. 26.00, OR= 1.183, p<0.001), median TFC (10.00 vs. 8.00, OR= 1.144, p<0.001). The ST group had more dysarthria, and worse cognitive and functional scores compared to the “no ST” group: dysarthria (32.2% vs 20.1%, OR= 1.883, p<0.001), mean correct Symbol Digit Modality Test (16.79 vs. 23.27, OR= 0.961, p<0.001), median TFC (6.00 vs. 9.00, OR= 0.884, p<0.001). Over one year, depression scores improved in psychotherapy/counseling patients compared to those untreated (-1.24 vs. -0.11, p= 0.040). ST patients experienced worsening depression scores (1.14 vs. -0.23, p=0.044). Mean change in TFC was not significant for any therapies.

Conclusion: Only 32% of patients at Enroll-HD sites received PT/OT, ST, or psychotherapy/counseling. Use correlated with expected clinical characteristics, although impact of use is unclear.

To cite this abstract in AMA style:

J. Yomtoob, C. Yeh, D. Bega. Ancillary Service Utilization and Impact in Huntington’s Disease [abstract]. Mov Disord. 2019; 34 (suppl 2). https://www.mdsabstracts.org/abstract/ancillary-service-utilization-and-impact-in-huntingtons-disease/. Accessed May 18, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/ancillary-service-utilization-and-impact-in-huntingtons-disease/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
      • Welcome to the MDS Abstracts Site
      • Effect of marijuana on Essential Tremor: A case report
      • Advanced Search
      • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
      • Covid vaccine induced parkinsonism and cognitive dysfunction
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley